These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22791166)

  • 1. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
    Takakuwa M; Iwamoto J
    Biol Pharm Bull; 2012; 35(7):1159-65. PubMed ID: 22791166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
    Hongo M; Miyakoshi N; Kasukawa Y; Ishikawa Y; Shimada Y
    J Bone Miner Metab; 2015 Jul; 33(4):432-9. PubMed ID: 25123562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.
    Iwamoto J; Makita K; Sato Y; Takeda T; Matsumoto H
    Osteoporos Int; 2011 Oct; 22(10):2735-42. PubMed ID: 21104227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.
    Fujita T; Ohue M; Nakajima M; Fujii Y; Miyauchi A; Takagi Y
    J Bone Miner Metab; 2011 Sep; 29(5):588-97. PubMed ID: 21455715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
    Oral A; Lorenc R;
    Acta Orthop Traumatol Turc; 2015; 49(1):67-74. PubMed ID: 25803256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
    Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
    J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
    Altintaş F; Ozkut AT; Beyzadeoğlu T; Eren A; Güven M
    Acta Orthop Traumatol Turc; 2007; 41(2):132-5. PubMed ID: 17483649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
    Yoshioka T; Okimoto N; Okamoto K; Sakai A
    J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
    Abe Y; Ishikawa H; Fukao A
    Tohoku J Exp Med; 2008 Jan; 214(1):51-9. PubMed ID: 18212487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of elcatonin versus nonsteroidal anti-inflammatory medications for acute back pain in patients with osteoporotic vertebral fracture: a multiclinic randomized controlled trial.
    Endo N; Fujino K; Doi T; Akai M; Hoshino Y; Nakano T; Iwaya T
    J Bone Miner Metab; 2017 Jul; 35(4):375-384. PubMed ID: 27465912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E; Karalok H; Tufekci EC; Batur O
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
    Iizuka T; Matsukawa M
    Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
    Zegels B; Eastell R; Russell RG; Ethgen D; Roumagnac I; Collette J; Reginster JY
    Bone; 2001 Jan; 28(1):108-12. PubMed ID: 11165950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periodontal assessment of postmenopausal women receiving risedronate.
    Palomo L; Bissada NF; Liu J
    Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
    Takada J; Iba K; Imoto K; Yamashita T
    J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.